HLA-A*24:02-restricted M-phase phosphoprotein 1 peptide epitope (HLA-A*24:02/MPHOSPH1)

The HLA-A*24:02-restricted M-phase phosphoprotein 1 (MPHOSPH1) peptide epitope is a specific antigen complex presented on the surface of cancer cells. MPHOSPH1, also known as KIF20B, is a kinesin-related protein essential for cytokinesis that is frequently overexpressed in various malignancies, including bladder, esophageal, and pancreatic cancers (PubMed: 21856905). When the MPHOSPH1-derived peptide (typically the 9-mer MPHOSPH1-941) is processed and presented by the HLA-A*24:02 molecule, it becomes a potent target for the cellular immune system (PubMed: 24633677). Therapeutic strategies, such as peptide-based vaccines like OTS102 and TCR-engineered T-cell therapies, aim to exploit this complex to induce a robust cytotoxic T-lymphocyte (CTL) response specifically against tumor cells (ClinicalTrials.gov: NCT00910325). Because the HLA-A*24:02 allele is highly prevalent in East Asian populations, this target is particularly significant for regional oncology drug development (Allele Frequency Net Database). Clinical studies have demonstrated that targeting this epitope can lead to the expansion of antigen-specific CTLs and potential anti-tumor activity in patients with advanced cancers (PubMed: 17631024).

Other names

MPHOSPH1-941 peptideKIF20B peptide epitopeHLA-A*24:02/KIF20B complexM-phase phosphoprotein 1 (941-949)MPHOSPH1-941/HLA-A*24:02

The target acts as a specific molecular signal for the immune system; drugs like peptide vaccines or TCR-engineered T-cells bind to or induce the recognition of this complex to trigger a cytotoxic T-lymphocyte (CTL) mediated attack against tumor cells presenting the epitope (PubMed: 24633677).